Thus, a pharmacovigilance unit in compliance with good pharmacovigilance practices, collects and monitors any adverse events notified by healthcare professionals in connection with our medicines. Reported cases are forwarded to the national pharmacovigilance center (CNPV) with which we are in close collaboration. Also, our medical representatives are trained on our internal pharmacovigilance procedure and are made aware of the importance of these notifications for the safety of our medicines. Alongside, the medical department ensures the relevance and reliability of the information conveyed by our medical representatives on our medicines, thanks to regular and updated medical training allowing our visitors to engage in a mode of relations respectful of the activity. and rules of medical ethics. We urge Healthcare Professionals and Patients to inform us of any suspected adverse reactions to our medicines.
We want to take this opportunity to thank you for your inquiry. Please note that any personal data provided by you will be treated by PHI with full respect of your privacy and you have the right to access your personal data. Any information you provide, including an adverse event or product quality complaint, may be shared with regulatory agencies, our company subsidiaries, and business partners with whom we have contractual agreements. These individuals may be located in a country other than yours.
In case you wish to access, amend or correct your personal health information, please contact us at (+212 537 64 83 64) or at (pharmacovigilance@phi.ma).